1	Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan
2	
3	Authors and academic degrees:
4	Dilyara Nabirova, ^{1,2} Roberta Horth, ^{1,2} Manar Smagul, ³ Gaukhar Nukenova, ³ Aizhan
5	Yesmagambetova ⁴ , Daniel Singer ^{1,2} , Alden Henderson ⁵ , Alexey Tsoy ⁴
6	
7	Affiliations:
8	1. U.S. Centers for Disease Control and Prevention, Central Asia Regional Office, Almaty,
9	Kazakhstan; hny5@cdc.gov; ORCID ID 0000-0002-0314-2202; hxw5@cdc.gov, ORCID ID
10	0000-0003-1810-2542; dps4@cdc.gov;
11	2. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan,
12	a. Scientific and practical center of sanitary-epidemiological examination and
13	monitoring, branch of the National Center for Public Health, Almaty, Kazakhstan;
14	gnukenova@mail.ru; manar.smagul@gmail.com,
15	3. Ministry of Healthcare, Nur-Sultan, Kazakhstan; yesmagambetovaa@gmail.com;
16	alex_tsoy@mail.ru
17	4. U.S. Centers for Disease Control and Prevention, Atlanta, USA; akh0@cdc.gov
18	
19	Correspondence: Dr. Dilyara Nabirova, U.S. Centers for Disease Control and
20	Prevention, Central Asia, Almaty, Kazakhstan; E-mail: hny5@cdc.gov
21	Disclaimer: The findings and conclusions in this report are those of the author(s) and do not
22	necessarily represent the official position of the U.S. Centers for Disease Control and Prevention
23	Word count: 3473

- 24 ABSTRACT (250/250)
- 25

26 BACKGROUND

27 In February 2021 Kazakhstan began offering COVID-19 vaccines to adults. Breakthrough

28 SARS-CoV-2 infections raised concerns about real-world vaccine effectiveness. We aimed to

29 evaluate effectiveness of four vaccines against SARS-CoV-2 infection.

30

31 METHODS

32 We conducted a retrospective cohort analysis among adults in Almaty using aggregated

vaccination data and individual-level breakthrough COVID-19 cases (\geq 14 days from 2nd dose)

34 using national surveillance data. We ran time-adjusted Cox-proportional-hazards model with

35 sensitivity analysis accounting for varying entry into vaccinated cohort to assess vaccine

36 effectiveness for each vaccine (measured as 1-adjusted hazard ratios) using the unvaccinated

population as reference (N=565,390). We separately calculated daily cumulative hazards for

38 COVID-19 breakthrough among vaccinated persons by age and vaccine month.

39

40 **RESULTS**

41 From February 22 to Sept 1, 2021 in Almaty, 747,558 (57%) adults were fully vaccinated

42 (received 2 doses) and 108,324 COVID-19 cases (11,472 breakthrough) were registered. Vaccine

43 effectiveness against infection was 78% (sensitivity estimates: 74–82%) for QazVac, 77% (72–

44 81%) for Sputnik V, 71% (69–72%) for Hayat-Vax, and 69% (64–72%) for CoronaVac. Among

45 vaccinated persons, the 90-day follow-up cumulative hazard for breakthrough infection was

46 2.2%. Cumulative hazard was 2.9% among people aged ≥ 60 years versus 1.9% among persons

47 aged 18–39 years (p<0.001), and 1.2% for people vaccinated in February–May versus 3.3% in

48 June–August (p<0.001).

49

50 CONCLUSION

51 Our analysis demonstrates high effectiveness of COVID-19 vaccines against infection in Almaty

52 similar to other observational studies. Higher cumulative hazard of breakthrough among people

53 >60 years of age and during variant surges warrants targeted booster vaccination campaigns.

54	What is already known on this topic
55	• Plenty of data are published on effectiveness of mRNA vaccines; however, these
56	vaccines were not widely available in many low- and middle-income countries in 2021.
57	• There are no real-world effectiveness studies on several vaccines available in the Central
58	Asia region, including QazVac vaccine, an inactivated vaccine developed by Kazakhstan.
59	• Understanding how these vaccines are performing outside of clinical trials is critical for
60	the COVID-19 response and lack of published data can contribute to vaccine hesitancy.
61	
62	What this study adds
63	• Our study demonstrated that at the population-level the four vaccines against COVID-19
64	used in Kazakhstan were effective at preventing SARS-CoV-2 infection.
65	• Vaccination reduced the risk of infection by 76% and prevented over 100,000 cases of
66	SARS-CoV-2 infection in Almaty, the country's most populous city.
67	• This is also the first study that demonstrated high vaccine effectiveness in real-world
68	conditions of QazVac, developed in Kazakhstan.
69	
70	How this study might affect research, practice or policy
71	• Policy makers in Kazakhstan and the Central Asia region need data on vaccines provided

72 in the region to update evidence-based vaccine guidelines for different populations.

73 INTRODUCTION

From March 2020 to December 17, 2021 in Kazakhstan, over one million people were diagnosed 74 with coronavirus disease 2019 (COVID-19); ~18,000 died.¹ Vaccines have become a key tool for 75 reducing COVID-19-associated morbidity and mortality and preventing transmission of SARS-76 CoV-2. In February 2021, Kazakhstan began offering COVID-19 vaccines to adults aged 18 77 years and older. By December 9, 2021, 71% of adults (~eight million people) had received at 78 least two doses of vaccines, including Sputnik V (Gam-COVID-Vac, Gamaleya Research 79 Institute of Epidemiology and Microbiology, Russia), QazVac (QazCovid-in, Research Institute 80 81 for Biological Safety Problems, Kazakhstan), CoronaVac (Sinovac Biotech, China), Sinopharm (BBIBP-CorV, Beijing Institute of Biological Products, China) and Hayat-Vax (BBIBP-CorV, 82 G42 Healthcare, United Arab Emirates).² 83

84

Of the five vaccines available in Kazakhstan, two (CoronaVac and Sinopharm) were listed for
emergency use globally by the World Health Organization (WHO) by end of 2021. The WHO
pre-qualifies and lists vaccines based on several guidelines³ including Good Manufacturing
Practice (GMP) and >50% vaccine efficacy in preventing SARS-CoV-2 outcomes in clinical
trials.^{4, 5} Among the WHO listed vaccines, vaccine efficacy against symptomatic disease in
randomized-controlled trials was 51-84% for CoronaVac, 79% for Sinopharm, 63-76% for
AstraZeneca, and >90% for Moderna and Pfizer–BioNTech vaccines.^{4, 5,6}

92

Although not listed by the WHO, Sputnik V and QazVac vaccines have received emergency use
authorization from the Kazakhstan Ministry of Health. They have shown interim efficacy of
>90% and safety in phase III and II clinical trials, respectively.⁷⁻¹⁰ Additionally, Sputnik V

demonstrated 79-86% effectiveness against infection and 85-93% effectiveness against COVID19 related death in a number of observational studies outside of clinical trials (real-world).^{11, 12}
98

99 Increasing breakthrough COVID-19 infections among vaccinated people raised concerns about the real-world effectiveness of available vaccines. By the end of 2021, there were no real-world 100 effectiveness studies on the QazVac vaccine and limited data on the effectiveness of Sputnik V. 101 102 Understanding how vaccines are performing outside of clinical trials is important for healthcare 103 system preparedness and mitigation strategies. Policy makers in Kazakhstan needed data to create evidence-based vaccine guidelines, including policies for booster vaccine doses for 104 different populations. We aimed to estimate daily hazard of breakthrough SARS-CoV-2 infection 105 among vaccinated people in Almaty, to identify groups at higher risk for breakthrough infection, 106 107 and to evaluate the overall effectiveness of four vaccines against infection.

108

109 METHODS

110 Study design

111 We conducted a retrospective, observational population-based cohort study of the vaccine

112 effectiveness of four different vaccines against SARS-CoV-2 infection among adults 18 years or

113 older in Almaty, Kazakhstan. Almaty is the economic capital and largest city of Kazakhstan with

an adult population of 1,313,040 (~10% of the national adult population).

115	Key definitions
116	A breakthrough COVID-19 infection was defined as having confirmed or probable COVID-19,
117	including people with asymptomatic disease, ≥ 14 days after receiving the 2 nd dose of a COVID-
118	19 vaccine.
119	
120	A confirmed COVID-19 case was defined as the detection of SARS-CoV-2 ribonucleic acid
121	(RNA) in a respiratory specimen collected from a person aged ≥ 18 years, including those with
122	asymptomatic disease.
123	
124	A probable COVID-19 case was a patient who met clinical criteria (chest imaging suggesting
125	COVID-19, anosmia, ageusia in the absence of any other identified cause), did not have a
126	positive SARS-CoV-2 PCR test, and was a contact of a probable or confirmed case or linked to a
127	COVID-19 cluster.
128	
129	Fully vaccinated was defined as having received two COVID-19 vaccine doses (there were no
130	single dose COVID-19 vaccines offered in Kazakhstan). Unvaccinated was defined as never
131	having received any COVID-19 vaccine. Partial vaccination was having received only one
132	vaccine dose. People who received only one dose were excluded from analysis.
133	
134	We classified people into four groups. People who were:
135	(1) unvaccinated (never received any COVID-19 vaccine) and diagnosed with COVID-19,
136	(2) unvaccinated (never received any COVID-19 vaccine) and not diagnosed with COVID-19,
137	(3) fully vaccinated (two doses) and diagnosed with breakthrough COVID-19, and

138 (4) fully vaccinated (two doses) and not diagnosed with breakthrough COVID-19.

140	Study population
141	Our analysis included Almaty residents ages 18 years and older. The following people were
142	excluded from analysis (Supplementary Figure 1):
143	• People that received only their first dose of vaccine and had a positive SARS-CoV-2 PCR
144	test <14 days after the first vaccine dose. ¹³
145	• People whose records were inconsistent with national vaccination guidelines (e.g. second
146	dose was <7 days of the first dose or they had COVID-19 diagnosis <25 days before their
147	second dose).
148	• People who received the Sinopharm vaccine (only 20 people).
149	• People who had SARS-CoV-2 PCR positive result <14 days after their second dose. This last
150	group was included in sensitivity analysis.
151	Data on history of COVID-19 prior to the study period was not available; therefore, we do
152	not exclude based on prior disease.
153	
154	Data sources
155	Individual-level data on COVID-19 cases among anyone who had ever received a COVID-19
156	vaccine were provided by the Emergency Operational Center (EOC) of the National Center of
157	Public Health of the Ministry of Health in Kazakhstan from February 1 to September 1, 2021.
158	Data on all COVID-19 cases from testing centers, laboratories, hospitals, and healthcare
159	providers are collected by the EOC. This clinical record dataset included age, comorbidities,
160	dates of COVID-19 vaccination, vaccine name, date of SARS-CoV-2 PCR test result or

diagnosis, hospitalization, death, and disease severity. Disease severity was based on the WHO
Scale adapted by the Kazakhstan clinical protocol of diagnosis and treatment. People with
critical disease had acute respiratory distress, those with severe disease had severe pneumonia,
those with moderate disease had pneumonia, and those with mild disease did not have
pneumonia. Data aggregated per day on SARS-CoV-2 polymerase chain reaction (PCR) testing,
which included the number of people testing positive per day for the same period, were also
provided.

168

Aggregated data on vaccination were received from the Salidat Kairbekova National Research
Center for Health Development of the Ministry of Health in Kazakhstan. Variables were
aggregated by date and included the number of people vaccinated per day per age group and
vaccine type.

173

174 Statistical analysis

Analyses were performed using R statistical software, version 4.0.3 (R Foundation for Statistical
Computing). We calculated and plotted attack rates for the vaccinated and unvaccinated
populations for each day of our analysis for each vaccine type. We fitted time-dependent Cox
proportional hazards regression models using the coxph() function of the survival package to
assess the time to COVID-19 diagnosis by vaccination status. Vaccine status was a timedependent covariate that changed when the person received their 1st dose and 14 days after their
2nd dose.

 $\lambda(t|Z(t)) = \lambda 0(t) exp\{\beta \ 0Z(t)\}$

182 The hazard at time t depends on the value of covariates at time Z(t). The regression effect of $Z(\cdot)$ 183 is constant β over time. The adjusted hazard ratio was exp{ $\beta 0Z(t)$ }. Adjusted vaccine effectiveness, measured as 1- $\exp\{\beta OZ(t)\}$, and adjusted for day and vaccine status, was 184 185 assessed for each of the 4 vaccines using the unvaccinated population as the reference group. 186 The time of entry into the model was set at February 1, 2021, when COVID-19 vaccines became 187 available in Almaty. The entire population of adults ≥ 18 years old in Almaty (N=1,313,040) was 188 classified into the unvaccinated group at-risk for COVID-19 group. People contributed person-189 time to the unvaccinated population until they either received a COVID-19 diagnosis or a 190 COVID-19 vaccine. After people received their first vaccine, they did not contribute person-time 191 to either population (vaccinated or unvaccinated) from their first dose to 14 days after their 192 second dose after which they contributed person-time to the vaccinated population. We 193 performed sensitivity analysis by changing the dates at which people entered the vaccinated 194 population (at first dose, second dose, second dose + 7 days or second dose + 14 days) and the 195 196 dates of definition of a COVID-19 breakthrough case (after second dose, second dose + 7 days or second dose + 14 days). We show sensitivity estimates throughout for our results to more 197 accurately express the uncertainty around estimates. 198

199

We separately calculated crude vaccine effectiveness for each vaccine using the followingformula:

crude VE

= $rac{(Incidence \ proportion \ among \ unvaccinated \ - \ Incidence \ proportion \ among \ vaccinated)}{Incidence \ proportion \ among \ unvaccinated}$

We also estimated the number of COVID-19 cases prevented by multiplying the number of
vaccinated people by the overall incidence among the unvaccinated population, and subtracting
the number of breakthrough cases.

206

207 Lastly, we conducted sub analysis on the vaccinated population, we calculated the cumulative

208 hazard percent of getting COVID-19 using survfit() and plotted Kaplan-Meyer cumulative

209 hazard curves using ggsurvplot() function and by vaccine name, age group, and month. The log-

210 rank test was used to test difference in hazard curves.

211

212 **RESULTS**

From February 22 to September 1, 2021 in Almaty, 747,558 residents aged ≥ 18 years were fully

vaccinated against COVID-19 with Sputnik-V (668,452), Hayat-Vax (42,437), CoronaVac

215 (22,181), or QazVac (14,488) and met inclusion criteria (supplement figure). During this time,

Almaty had 108,324 probable and confirmed COVID-19 cases among people \geq 18 years old,

including 23,858 cases among people with at least one COVID-19 vaccination record

(supplement figure). Of these 11,472 were fully vaccinated and met criteria for breakthrough

219 SARS-CoV-2 infection.

220

Among fully vaccinated people with breakthrough SARS-CoV-2 infections (table 1), 24% were ≥ 60 years old and 11% had a known comorbidity and presence of comorbidity was unknown for 72%. The median interval between vaccine doses was 21 days (range 8–166). The median interval between second dose and breakthrough infection was 59 days (range 14–178). Disease

- was classified as critically severe for 0.7% and severe for 6.8% of cases, and 29% were
- hospitalized. There were 120 deaths (1%).
- 227 **Table 1** Characteristics of fully vaccinated people with SARS-CoV-2 breakthrough infection,

Almaty, Kazakhstan, 2021

Characteristics	N=11,472	% or (range)
Sex		
Female	6,923	60.3
Male	4,549	39.7
Age, median (range)°	45	(range 18 to 96)
18-39 years	4,360	38.0
40-59 years	4,351	37.9
\geq 60 years	2,761	24.1
Had a comorbidity		
No	1,892	16.5
Yes	1,271	11.1
Unknown	8,309	72.4
Fully vaccinated	-,	
Sputnik V	9,826	85.7
Hayat-Vax	955	8.3
QazVac	187	1.6
CoronaVac	504	4.4
COVID-19 waves in Kazakhstan	501	
February 1- June 30, 2021	402	3.5
July 1- 31, 2021	2,335	20.4
August 1- September 1, 2021	8,735	76.1
PCR-identified cases	0,755	70.1
PCR -	560	4.9
PCR +	10,912	95.1
Interval between 1st and 2nd dose in days, median (range)	21	(range 8 to166)
8-14 days	259	(Talige 8 (0100) 2.3
15-19 days	395	3.4
20-25 days	8,449	73.6
26-46 days	1,906	16.6
47-166 days	463	4.0
	403 59	(range 14 to 178)
Days since fully vaccinated to disease onset COVID-19 severity*	39	(Talige 14 to 178)
Critical disease	78	0.7
Severe disease	78 776	0.7 6.8
Moderate disease	2,154	18.8
Mild disease	8,464	73.8
Hospitalized	0.146	71.0
No	8,146	71.0
Yes	3,326	29.0
Number of hospitalizations**	2 205	00.0
One hospitalization	3,285	98.8
Two hospitalizations	41	1.2
Length of hospitalization in days, median (range)**	9	(range 1 to35)
Outcome	11.0	~~~~
Recovered or transferred	11,352	99.0
Died	120	1.0

* WHO Scale adapted by the Kazakhstan clinical protocol of diagnosis and treatment (Coronavirus infection COVID-19 in adults);**Subset of persons having been hospitalized

- Vaccination began on February 1, 2021 for Sputnik, April 25 for QazVac, May 3 for Hayat-Vax
- and June 6 for CoronaVac. During the study period, the adjusted vaccine effectiveness for all
- four vaccines was 76% (low and high sensitivity percent range of 71.1–80.0%) (table 2).
- Adjusted vaccine effectiveness varied by vaccine and was 77.0% (71.4–80.8%) for Sputnik V,
- 233 78.6% (74.2–82.0%) for QazVac, 71.2% (69.3–73.0%) for Hayat-Vax, and 69.5% (64.7–71.5%)
- for CoronaVac (p < 0.001).
- 235
- Table 2. Vaccine effectiveness against SARS-CoV-2 infection of four COVID-19 vaccines in
- 237 Almaty, Kazakhstan, 2021

Cotogony	N %aVE		6 aVE 95% CI		Sensitivity	% cVE	95% CI		
Category	IN	70 ave	95% CI	Low	95% CI	High	95% CI	70 CVE	95% CI
Vaccine status									
Vaccinated	747,558	76.4*	(75.9-76.9)	71.1	(70.5-71.6)	80.0	(79.6-80.4)	89.7	(89.5-89.9)
Not vaccinated	565,370	Ref						Ref	
Vaccine name									
QazVac	14,488	78.6*	(75.3-81.4)	74.2	(70.2-77.7)	82.0	(79.2-84.4)	85.8	(83.6-87.7)
Sputnik-V	668,452	77.0*	(76.5-77.5)	71.4	(70.8-72.1)	80.8	(80.4-81.2)	90.4	(90.2-90.6)
Hayat-Vax	42,437	71.2*	(69.3-73.0)	69.1	(67.1-71.0)	72.4	(70.6-74.1)	73.2	(71.4-74.8)
CoronaVac	22,181	69.5*	(66.7-72.0)	64.7	(61.5-67.7)	71.5	(68.9-73.9)	71. 1	(68.5-73.5)
Not vaccinated	565,370	Ref						Ref	

238

*Time-dependent Cox-proportional hazards log-rank test P-value <0.001

240 aVE: adjusted vaccine effectiveness, adjusted for time and vaccine status

241 CI: Confidence Interval

Low: day of contribution of person-time to vaccinated population begins on day of 1st dose

High: day of contribution of person-time to vaccinated population begins 14 days after 2nd dose

cVE: crude vaccine effectiveness; persons partially vaccinated (n=7482) and those with a case registered

before February 22, 2021 (n=2018) were excluded from the unvaccinated reference group

246	For all vaccines, the attack rate for COVID-19 per 100,000 was consistently higher over the 7-
247	day moving average for unvaccinated persons than for vaccinated persons (figure 1). The 7-day
248	moving average of daily vaccine effectiveness for all four vaccines remained above the WHO
249	50% threshold for vaccine efficacy ⁵ , except for one-week dips for QazVac in June and for
250	CoronaVac and Hayat-Vax in August. Based on overall incidence in the study period,
251	vaccination with these four vaccines prevented 100,213 cases of SARS-CoV-2 breakthrough
252	infection in Almaty.
253	
254	Figure 1. Cumulative vaccinated, vaccine effectiveness against SARS-CoV-2 infection, and
255	attack rates among vaccinated and unvaccinated populations by four COVID-19 vaccines in
256	Almaty, Kazakhstan, 2021
257	
258	Among people who were fully vaccinated (n=747,558), the 90-day cumulative hazard of
259	developing a SARS-CoV-2 breakthrough infection was 2.2%, ranging from 2.0% for Sputnik V
260	to 3.5% for Hayat-Vax (table 3). The cumulative hazard was significantly different by age group.
261	For people 60 years old and older the cumulative hazard was double that of people 18–39 years
262	old at the 180-day (12.8% vs 5.0%, respectively) and 90-day follow-ups (2.9% vs 1.9%).

Table 3. Cumulative hazard of SARS-CoV-2 breakthrough infection among persons fully

Group	N	Cumulative Hazard Percent					nt	Trend Line	Dualua	
Group	IN	Day	30	60	90	120	150	180	Trena Line	P-value
All vaccine	747 558		0.5%	1.2%	2.2%	3.9%	5.1%	6.7%		<0.001
Sputnik	668 452		0.4%	1.0%	2.0%	3.7%	4.9%	6.5%		
QazVac	14 488		0.5%	1.4%	2.5%	3.5%				
Hayat	42 437		0.4%	2.0%	3.5%				/	
CoronaVac	22 181		1.0%	2.6%					/	
Age										<0.001
18-39	387 024		0.4%	1.1%	1.9%	2.9%	3.8%	5.0%		
40-59	272 225		0.5%	1.2%	2.2%	3.9%	5.2%	6.8%		
60+	88 309		0.5%	1.4%	2.9%	5.9%	8.8%	12.8%		
Month										<0.001
Feb	1 171		0.1%	0.3%	0.8%	0.9%	1.3%	2.7%	^	
Mar	2 844		0.3%	0.5%	0.6%	1.0%	2.1%	3.8%	^	
Apr	53 371		0.1%	0.2%	0.7%	2.3%	3.6%			
May	147 046		0.1%	0.3%	1.3%	3.0%				
Jun	105 171		0.3%	1.5%	2.7%				/	
Jul	221 353		0.8%	2.0%					/	
Aug	208 821		0.6%						*	
Sep	7 781									

vaccinated by four COVID-19 vaccines, Almaty, Kazakhstan, 2021

266	This divergence in hazard by age group over follow-up time was observed across the four
267	vaccines (p<0.001) (figure 2). Cumulative hazard curves began to diverge by age at
268	approximately 90 days postvaccination for Sputnik V, and at approximately 30 days
269	postvaccination for other vaccines. Cumulative hazard is also significantly different by study
270	period (p<0.001) when comparing people who were vaccinated in March to May 2021 to those
271	vaccinated in June to September 2021 (the period when the SARS-CoV-2 Delta variant was
272	active in the region). However, in vaccine-specific analysis, this difference was only significant
273	for QazVac and Sputnik V.

Figure 2. Cumulative hazard curves by age group and period of 2nd dose by vaccine type by 4
COVID-19 vaccines, Almaty, Kazakhstan, 2021

276

277 **DISCUSSION**

278 Our study demonstrated that at the population-level the four vaccines against COVID-19 used in

279 Kazakhstan were effective at preventing SARS-CoV-2 infection. Vaccination reduced the risk of

infection by 76% and prevented over 100,000 cases of SARS-CoV-2 infection in Almaty, the

country's most populous city. The vaccine effectiveness for all four vaccines exceeded the 50%

vaccine efficacy minimum threshold set by the WHO for approving vaccines. Vaccine

effectiveness also remained relatively stable over the period, despite a slight decrease observed

during the months when the SARS-CoV-2 Delta variant became the predominant circulating

strain worldwide.

286

QazVac had 79% vaccine effectiveness in our study, but accounted for only 2% of people
vaccinated. Vaccine effectiveness for QazVac in our analysis was similar to the vaccine efficacy
reported in phase III clinical trials (81%).¹⁰

290

The predominant vaccine given in Kazakhstan during the period of analysis was Sputnik V (89% of vaccinated people) and our observed vaccine effectiveness of 73% compares to (79% and 86%) vaccine effectiveness from limited observational studies, but lower than 92% vaccine efficacy estimate from phase III clinical trials. However, these clinical trials took place before Delta became the predominant variant.^{8, 11, 12}

297 CoronaVac had the lowest vaccine effectiveness in our analysis, and the estimate fell within the range of vaccine efficacy phase III trials (51% to 84%) in several countries.^{6, 14-17} It is also 298 consistent with vaccine effectiveness against symptomatic disease reported in a comparable 299 study from Chile (66%).¹⁸ Vaccine effectiveness for Hayat-Vax (71%) was also within the range 300 of vaccine effectiveness reported in similar studies in Hungary and Peru (69% and 50%, 301 respectively)^{11, 19} and vaccine efficacy reported by Sinopharm (the same BBIBP-CorV vaccine 302 manufactured in China) for phase III clinical trials (79%).^{6, 20} 303 304 Although COVID-19 vaccines used globally are highly effective, people who are fully 305 vaccinated may experience breakthrough SARS-CoV-2 infections, especially when the incidence 306 is high, and the proportion of people vaccinated in a population is low. In Kazakhstan, 307 population vaccination began shortly before the Delta surge. As expected, breakthrough cases 308 309 occurred among vaccinated people, increasing as SARS-CoV-2 incidence increased in the 310 country. However, out of every 100 people fully vaccinated in Almaty during our study period 311 less than 2 had breakthrough infections. The low proportion of people getting breakthrough

COVID-19 in our study is within the range of that reported in other settings (<1 to 8%).^{21, 22} Not only are vaccines effective for reducing infection, they are also highly effective at reducing morbidity and mortality; ^{23, 24} in our study, the majority of people with breakthrough infection had mild disease.

316

Proportion of breakthrough infections increased over time, especially among people >60 years of age and during the SARS-CoV-2 Delta variant surge.^{6, 25} This increase was most notable among people vaccinated with Sputnik V because it had the longest period of follow-up, but the followup period was limited to <90 days for 2 of the 4 vaccines studied. We cannot distinguish whether
the declining effectiveness was attributable to waning immunity or emergence of new SARSCoV-2 variants. However, waning immunity has been demonstrated in several studies that found
reduced neutralizing antibodies over time in people vaccinated against COVID-19 with
CoronaVac, Sputnik V, and BNT162b2 (Hayat-Vax) vaccines, and others.^{6, 26} Our results align
with Kazakhstan's recommendation to offer booster vaccinations for older populations, and with
CDC and WHO recommendations for booster doses for all vaccinated adults.

During data cleaning, we found 1,204 cases where the dates of vaccination and disease onset 328 conflicted with national vaccine administration directives. While some errors could be recording 329 problems, many are likely falsified certification of vaccinations (fake vaccine passports). Fake 330 vaccine passports are known problems in the Central Asia Region and in Kazakhstan.²⁷⁻²⁹ The 331 fake vaccine passports undermine efforts to mitigate COVID-19. Falsification occurs in part 332 because authorities have required COVID-19 vaccinations for certain populations, but vaccine 333 334 confidence is low. Data on real-word effectiveness of vaccines may help address low vaccine confidence. 335

336

Vaccine confidence can also be boosted through increased global recognition of efficacious vaccines. Despite trials showing high vaccine efficacy and studies showing real-world vaccine effectiveness in several countries, only 1 of the 4 vaccines in our study, CoronaVac, is accepted as proof of vaccination in several countries. The other vaccines, 2 of which have been used widely globally, have not completed submission of all requirements for WHO approval.

343 Strengths and limitations

This is the first study from Kazakhstan reporting the real-world effectiveness of fours available vaccines based on the retrospective cohort analysis in the largest city of the country using aggregated vaccination data and individual-level breakthrough case national surveillance data. Three of these studied vaccines are not accepted for international travel by most governments worldwide. This is also the first study to estimate vaccine effectiveness for QazVac, an inactivated vaccine developed in Kazakhstan, in real-world conditions. Our results are relevant for planning and scale-up of COVID-19 vaccination efforts in the region.

351

352 Our study is subject to at least five important limitations. First, we could not assess vaccine effectiveness against severe disease, hospitalization, and death because individual level data on 353 354 unvaccinated people who died or were hospitalized were not available for our analysis. Second, 355 we were not able to adjust for potential confounders, such as age or underlying medical 356 conditions, because this data was not available. Our analysis is likely not biased by age because 357 the population proportion ages 60 years and older among vaccinated people (12%) approximates that proportion in the general adult population.³⁰ Additionally, the analysis captures 57% of the 358 vaccinated population. Third, when only people with symptoms of COVID-19 test, vaccine 359 effectiveness may be overestimated. However, testing was widely available in Almaty during the 360 study period, with no documented shortages. There were no changes in testing policy over this 361 time, and proof of COVID-19 negative test results were required for participation in several 362 363 activities. Also, the seven-day moving average of COVID-19 tests tracked the epidemic curve. Fourth, individual data was available only for COVID-19 cases among vaccinated people and 364 365 cases among unvaccinated people were aggregate. We could not remove potential duplicates

from aggregated COVID-19 case data. Fifth, though we attempted to remove fake vaccine
passports from the analysis, we cannot ascertain status of all vaccine records and people who
were not vaccinated may have been included in the vaccinated population.

369

370 CONCLUSION

We found that 4 vaccines used in Almaty were highly effective against SARS-CoV-2 infection. Our results may help increase vaccine confidence in Kazakhstan and the region. Scale-up of efforts to fully vaccinate all eligible unvaccinated persons and to providers booster doses to persons already fully vaccinated, people >60 years of age and during variant surges, will help reduce SARS-CoV-2 incidence.

376

Contributors: DN, RH, MS, GN, AY, DS, AH and AT conceived and designed the study. DN,
RH, and GN did the statistical analysis. MS, GN, AY, and AT were responsible for data curation.
DN, RH, AH, and DS searched the existing literature. DN, RH, and AH wrote the original draft
of the manuscript and all authors reviewed and edited the manuscript for intellectual content. DN
and RH prepared data visualization. AY, DS, and AT were responsible for study administration.
The corresponding author confirms that all listed authors meet authorship criteria and that no
others meeting the criteria have been omitted.

384

385 **Funding**: None.

386

387 Competing interests: All authors have completed the ICMJE uniform disclosure form at

388 www.icmje.org/coi_disclosure.pdf and declare no conflict of interest; no support from any

389 organization for the submitted work; no financial relationships with any organizations that might

390	have an interest in the submitted work in the previous three years; no other relationships or
391	activities that could appear to have influenced the submitted work.

392

393	Ethical approval: The study was deemed non-research public health activity by the MoH of
394	Kazakhstan and the institutional review board of CDC and conducted in accordance with CDC
395	policy (project ID 0900f3eb81e4b259)
396	
397	Data sharing: The authors cannot share individual level data due to the national data protection
398	regulations. Deidentified data might be made available for authorized researchers after
399	application to the Ministry of Healthcare of the Republic of Kazakhstan.
400	The authors confirm that the manuscript is an honest, accurate, and transparent account of the
401	investigation being reported; and that no important aspects of the study have been omitted.
402	
403	Dissemination to participants and related patient and public communities: The Ministry of
404	Healthcare of the Republic of Kazakhstan and the authors will disseminate the study findings
405	through press releases, a website (https://rk-ncph.kz/ru/), and through social media.
406	
407	Provenance and peer review: Not commissioned; externally peer reviewed.
408	
409	References
410 411 412	1. World Health Organization Health Emergency Dashboard. Kazakhstan Situation. Data as received by WHO from national authorities by 5:51pm CET, 17 December 2021. Available at https://covid19.who.int/region/euro/country/kz.

413 2. Over 8 million Kazakhstanis fully vaccinated against coronavirus. November 30, 2021. Available

414 at https://primeminister.kz/en/news/bolee-8-mln-kazahstancev-polnostyu-vakcinirovalis-ot-

415 <u>koronavirusa-30103645</u>.

- 416 3. Zahid MN, Moosa MS, Perna S, Buti EB. A review on COVID-19 vaccines: stages of clinical trials,
- 417 mode of actions and efficacy. Arab Journal of Basic and Applied Sciences. 2021 2021/01/01;28(1):225418 33.
- 419 4. World Health Organization. Vaccine efficacy, effectiveness and protection. 14 July 2021.
- 420 Available at <u>https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-</u>
 421 protection.
- 422 5. World Health Organization. Considerations for evaluations of COVID-19 vaccines. Points to
- 423 consider for manufacturers of COVID-19 vaccines. Version 23 September 2020. Avaiable at
- 424 <u>https://www.who.int/medicines/regulation/prequalification/prequal-</u>
- 425 <u>vaccines/WHO Evaluation Covid Vaccine.pdf</u>.
- 4266.Mallapaty S. China's COVID vaccines have been crucial now immunity is waning. Nature. 2021427Oct;598(7881):398-9. PubMed PMID: 34650240. eng.
- Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021
 Feb 20;397(10275):642-3. PubMed PMID: 33545098. Pubmed Central PMCID: PMC7906719. Epub
 2021/02/06.
- 431 8. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin Al, Zubkova OV, Dzharullaeva AS, et al.
- 432 Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an
- 433 interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671-
- 434 81. PubMed PMID: 33545094. Pubmed Central PMCID: PMC7852454. Epub 2021/02/06.
- 435 9. Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, et al. Safety
 436 and immunogenicity of a QazCovid-in[®] inactivated whole-virion vaccine against COVID-19 in healthy
 437 adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2
- 438 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021 2021/09/01/;39:101078.
- 10. Khairullin, Berik and Zakarya, Kunsulu and Orynbayev, Mukhit and Abduraimov, Yergali and
- 440 Kassenov, Markhabat and Sarsenbayeva, Gulbanu and Sultankulova, Kulyaisan and Cherviyakova, Olga
- 441 and Myrzhakhmetova, Balzhan and Nakhanov, Aziz and Nurpeisova, Ainur and Zhugunissov, Kuandyk
- and Assanzhanova, Nurika and Nurabayev, Sergazy and Kerimbayev, Aslan and Ershebulov, Zakir and
 Burashev, Yerbol and Kulmagambetov, Ilyas and Davlyatshin, Timur and Sergeeva, Maria and Buzitskaya,
- 444 Zhanna and Stukova, Marina and Kutumbetov, Lespek, Efficacy and Safety of an Inactivated Whole-
- 445 Virion Vaccine Against COVID-19, QazCovid-in[®], In Healthy Adults: A Multicentre, Randomised, Single-
- Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-Up. Available at SSRN:
- 447 <u>https://ssrn.com/abstract=4016484</u> or <u>http://dx.doi.org/10.2139/ssrn.4016484</u>.
- Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, et al. Nationwide effectiveness of five SARS CoV-2 vaccines in Hungary The HUN-VE study. Clinical Microbiology and Infection.
- 450 12. González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L, et al. Effectiveness of the first
- 451 component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections,
- 452 hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina.
- 453 EClinicalMedicine. 2021 Oct;40:101126. PubMed PMID: 34541480. Pubmed Central PMCID:
- 454 PMC8435263. Epub 2021/09/21. eng.
- 455 13. Jacobson KB, Pinsky BA, Montez Rath ME, Wang H, Miller JA, Skhiri M, et al. Post-Vaccination
 456 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the
- 457 Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic 458 Medical Center. Clinical Infectious Diseases. 2021.
- 458 Medical Center. Clinical Infectious Diseases. 2021.
 459 14. de Faria E, Guedes AR, Oliveira MS, de Godoy Moreira MV, Maia FL, dos Santos Barboza A, et al.
- Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) preliminary
 report. medRxiv. 2021:2021.04.12.21255308.
- 462 15. World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. FOR
 463 RECOMMENDATION BY THE STRATEGIC ADVISORY GROUP OF EXPERTS (SAGE) ON IMMUNIZATION.

464 April 29, 2021. Available at https://cdn.who.int/media/docs/default-465 source/immunization/sage/2021/april/5 sage29apr2021 critical-evidence sinovac.pdf. 466 Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, 16. observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of 467 468 SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. 469 Vaccine. 2021 Oct 22;39(44):6520-8. PubMed PMID: 34620531. Pubmed Central PMCID: PMC8461222. 470 Epub 20210924. eng. 471 Tanriover MD, Doganay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an 17. 472 inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, 473 placebo-controlled, phase 3 trial in Turkey. The Lancet. 2021;398(10296):213-22. 474 18. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an 475 Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine. 2021 Sep 2;385(10):875-476 PubMed PMID: 34233097. Pubmed Central PMCID: PMC8279092. Epub 20210707. eng. 477 19. Silvia-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernández-Navarro M, Moscoso-Porras M, 478 Solari L, et al. (22 July 2021). Efectividad de la vacuna BBIBP-CorV para prevenir infección y muerte en 479 personal de salud [Effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health 480 personnel] (Technical report) (in Spanish). Tabla 4, figura 2: Ministry of Health of Peru. 481 20. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated 482 SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. Jama. 483 2021 Jul 6;326(1):35-45. PubMed PMID: 34037666. Pubmed Central PMCID: PMC8156175. eng. 484 21. CTV News. What do we know about breakthrough COVID-19 cases? Experts break down the 485 science. Agusyt 26, 2021. Available at https://www.ctvnews.ca/health/coronavirus/what-do-we-know-486 about-breakthrough-covid-19-cases-experts-break-down-the-science-1.5561879. 487 22. New York State Department of Health. COVID-19 Breakthrough Data. Current estimates of cases 488 and hospitalizations by vaccine status, and vaccine effectiveness. Avaialble at 489 https://coronavirus.health.ny.gov/covid-19-breakthrough-data. 490 23. Team CC-VBCI. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, 491 January 1-April 30, 2021. MMWR Morbidity and mortality weekly report. 2021 May 28;70(21):792-3. 492 PubMed PMID: 34043615. Pubmed Central PMCID: PMC8158893 Journal Editors form for disclosure of 493 potential conflicts of interest. No potential conflicts of interest were disclosed. Epub 2021/05/28. 494 Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al. 24. 495 COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 496 2·57 million people in Scotland (EAVE II): a prospective cohort study. The Lancet Respiratory 497 Medicine. 2021;9(12):1439-49. 498 25. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral 499 Response to BNT162b2 Covid-19 Vaccine over 6 Months. New Engl J Med. 2021;385(24):e84. 500 26. Lapa D, Grousova D, Matusali G, Meschi S, Colavita F, Bettini A, et al. Retention of Neutralizing 501 response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals. medRxiv. 502 2022:2022.01.15.22269335. 503 27. Kazakhstan is awash in fake vaccination passports. July 24th 2021. Availble at 504 https://www.economist.com/asia/2021/07/24/kazakhstan-is-awash-in-fake-vaccination-passports. 505 28. Jonathan Greig, Staff Writer, Price for fake COVID-19 vaccine cards and passports drops to \$100:

report. ZDNet Security. Available at <u>https://www.zdnet.com/article/price-for-fake-covid-19-vaccine-</u>
 <u>cards-and-passports-drops-to-100-report/</u>.


508 29. Belovolchenko Hanna, Coronavirus Vaccines and Covid Passports Are Being Sold on the Dark

509 Web: Zaborona reports on cost and availability in Ukraine. Available at

- 510 <u>https://zaborona.com/en/coronavirus-vaccines-and-covid-passports-are-being-sold-on-the-dark-web-</u>
- 511 <u>zaborona-reports-on-cost-and-availability-in-ukraine/</u>.


- 512 30. World Bank staff estimates based on age/sex distributions of United Nations Population
- 513 Division's World Population Prospects: 2019 Revision. Population ages 65 and above (% of total
- 514 population) Kazakhstan. Available at
- 515 <u>https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=KZ</u>.

Figure 1. Cumulative vaccinated, vaccine effectiveness against SARS-CoV-2 infection, and attack rates among vaccinated and unvaccinated populations by 4 COVID-19 vaccines in Almaty, Kazakhstan, 2021



A – COVID-19 testing count, vaccinated population count, vaccine effectiveness (VE) and attack rates (AR)

B - Vaccinated population count, vaccine effectiveness (VE) and attack rates (AR) per vaccine



PP: Percent positive rolling 7-day average

VE: Vaccine effectiveness

SE: Low and high sensitivity estimates

AR: Attack rates per 100,000 people

N: The cumulative count of people vaccinated

Points represent the daily values and lines the moving 7-day averages.

Dotted line is at 50% vaccine effectiveness

Orange is the unvaccinated population and blue the vaccinated population

